Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • Haiti(0/week)
    • Guyana(0/week)
    • Honduras(0/week)
    • Jamaica(0/week)
    • Netherlands Antilles(0/week)
    • View all (0/week)
  • News
    • United States(1123/week)
    • Manufacturing(540/week)
    • Energy(431/week)
    • Technology(1037/week)
    • Other Manufacturing(333/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

Gliflozin

Dec 18, 2018
TriNetX Real-World Evidence Platform Validates Outcomes of Randomized Clinical Trials
Nov 26, 2018
Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway
Nov 10, 2018
Forxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE-TIMI 58 trial
Nov 05, 2018
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Oct 30, 2018
U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
Oct 10, 2018
New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease
Oct 04, 2018
Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
Jul 19, 2018
Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint
Jul 16, 2018
Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings
Jul 13, 2018
U.S. FDA Extends Review Timeline for INVOKANA® (canagliflozin) Supplemental New Drug Application
Jun 25, 2018
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
Jun 24, 2018
Real World Study Suggests Canagliflozin Does Not Increase Risk of Below-Knee Amputation in People with Type 2 Diabetes
Jun 24, 2018
Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Jun 24, 2018
Dapagliflozin as Adjunct Therapy to Insulin for People with Type 1 Diabetes May Improve Glycemic Control
Jun 24, 2018
Sotagliflozin in Conjunction with Insulin for Type 1 Diabetes Reduces Average Blood Glucose Levels
Jun 23, 2018
Real-World Evidence Shows Oral INVOKANA® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients
Jun 12, 2018
Johnson & Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc.
Jun 08, 2018
New Late-Breaking Data on the Use of Type 2 Diabetes Treatment INVOKANA® (canagliflozin) in the Real World Will Be Presented at the American Diabetes Association's 78th Annual Scientific Sessions
May 29, 2018
Invokana: The Diabetic Drug That Costs a Limb
May 24, 2018
New Review of the Real-world Data on the Cardiovascular Benefits Associated with the Use of Sodium-glucose Cotransporter 2 Inhibitors - touchENDOCRINOLOGY
  •  
  • Page 1
  • ››

Latest News

Jul 17, 2025

Toshiba Releases Automotive Photorelay with 1800V Output Withstand Voltage

Jul 17, 2025

UFP Industries to Report Second Quarter 2025 Results on Monday, July 28, 2025

Jul 17, 2025

Kobelco Construction Machinery Digitally Transforms Demand and Supply Planning Capabilities With Blue Yonder...

Jul 17, 2025

Entegris to Report Results for Second Quarter of 2025 on Wednesday, July 30, 2025

Jul 17, 2025

Black Stone Minerals, L.P. Announces Distribution and Schedules Earnings Call to Discuss Second Quarter 2025...

Jul 17, 2025

NVE Schedules Conference Call on First Quarter Results

Jul 17, 2025

Power Integrations to Release Second-Quarter Financial Results on August 6

Jul 17, 2025

Merz makes first trip to London amid warming post-Brexit ties

View all News

Agenda

30
September
PortugalTroia, Portugal
Seabed Security, 30 September - 01 October 2025, Troia, Portugal
Seabed Security | 30 September - 01 October 2025 | Troia, Portugal Defence iQ Announces Inaugural Seabed Security...
23
September
United KingdomLondon, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
View All Events

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
  • PRIVACY POLICY
  • INFORMATION SECURITY POLICY
© 2025 EPICOS
Made by Wedia